<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02042001</url>
  </required_header>
  <id_info>
    <org_study_id>IN-IT-264-1331</org_study_id>
    <nct_id>NCT02042001</nct_id>
  </id_info>
  <brief_title>Switching From Efavirenz/Atripla to Rilpivirine Among Patients With Neurocognitive or Neuropsychological Side Effects</brief_title>
  <acronym>SWEAR</acronym>
  <official_title>A Pilot Randomized Controlled Trial of Switch to Tenofovir Disoproxil Fumarate/Emtricitabine/Rilpivirine (TDF/FTC/RPV) Versus Continue Efavirenz (EFV)-Based Treatment Among Virologically Suppressed, HIV-1 Infected Subjects With Mild or Asymptomatic EFV-related Neurocognitive or Neuropsychological Side Effects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Azienda Ospedaliera San Gerardo di Monza</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Azienda Ospedaliera San Gerardo di Monza</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Despite long-term use in clinical practice, chronic treatment with efavirenz (EFV) has been
      associated with persistent central nervous system symptoms or mild or even asymptomatic
      neurocognitive impairment. Whether switching to rilpivirine (RPV) containing regimen is
      beneficial among patients who experience mild or asymptomatic neurocognitive/neuropsychiatric
      adverse events during EFV has not been explored yet.

      The proposed pilot study will examine whether switching from EFV-based regimen to single
      tablet regimen TDF/FTC/RPV is associated with neurocognitive/neuropsychiatric improvement
      among HIV-infected patients with mild/asymptomatic neurocognitive impairment or
      neuropsychiatric symptoms during EFV-containing antiretroviral treatment.

      Patients under stable treatment with EFV, confirmed HIV-1 RNA viral load &lt; 50 copies/mL and
      altered scores in depression, quality of sleep or anxiety tests and/or alteration in 1 or
      more domains as assessed by neuropsychological assessment, will be randomized to immediate or
      deferred (12 weeks) switch to TDF/FTC/RPV. Neurocognitive and neuropsychiatric tests will be
      repeated after 12 and 24 weeks of follow-up and variations will be compared between groups.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>April 2014</start_date>
  <primary_completion_date type="Anticipated">September 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Neuropsychiatric side effects</measure>
    <time_frame>24 weeks</time_frame>
    <description>Proportion of patients with improvement in depression, anxiety or quality of sleep scores, evaluated either as a binary (Yes/No) or on a continuous scale</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Neurocognitive side effects</measure>
    <time_frame>24 weeks</time_frame>
    <description>- Proportion of patients with improvement in neurocognitive performances in either one of the 7 domains investigated, evaluated either as a binary (Abnormal/Normal) or on a continuous scale (deficit score)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Composite neuropsychiatric/neurocognitive</measure>
    <time_frame>24 weeks</time_frame>
    <description>Proportion of patients with improvement in either one of the previous binary end-point (composite end-point)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Symptoms</measure>
    <time_frame>24 weeks</time_frame>
    <description>Proportion of patients with self-reported improvement in treatment-related symptoms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>24 weeks</time_frame>
    <description>Proportion of patients with self-reported improvement in quality of life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognitive failure</measure>
    <time_frame>24 weeks</time_frame>
    <description>Proportion of patients with improvement in Cognitive Failure Questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Viral suppression</measure>
    <time_frame>12 weeks</time_frame>
    <description>Proportion of patients with HIV-RNA &lt;50 copies/ml after 12 weeks of treatment (ITT-M=F)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Viral failure</measure>
    <time_frame>12 weeks</time_frame>
    <description>Proportion of patients with HIV-RNA &lt;400 copies/ml after 12 weeks (ITT-M=F)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Virological efficacy</measure>
    <time_frame>24 weeks</time_frame>
    <description>Proportion of patients with HIV-RNA &lt;50 copies/ml after 24 weeks (ITT-M=F)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety &amp; Tolerability</measure>
    <time_frame>24 weeks</time_frame>
    <description>Proportion of patients discontinuing treatment for intolerance to study drugs or due to side effects</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Resistance</measure>
    <time_frame>12 &amp; 24 weeks</time_frame>
    <description>Number of patients with genotypic resistance at failure</description>
  </other_outcome>
  <other_outcome>
    <measure>Immunological response</measure>
    <time_frame>12 &amp; 24 weeks</time_frame>
    <description>Change From Baseline in CD4+ and CD8+ T-Lymphocyte Cell Counts at Weeks 12 and 24</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Impaired Cognition</condition>
  <condition>Depression/Anxiety</condition>
  <condition>Poor Quality Sleep</condition>
  <condition>Quality of Life</condition>
  <condition>HIV-1 Infection</condition>
  <arm_group>
    <arm_group_label>Immediate Switch</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Immediate switch to TDF/FTC/RPV</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Deferred Switch</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Switch to TDF/FTC/RPV after 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Immediate switch to TDF/FTC/RPV</intervention_name>
    <arm_group_label>Immediate Switch</arm_group_label>
    <other_name>Eviplera (r)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Switch to TDF/FTC/RPV after 12 weeks</intervention_name>
    <description>Patients will continue current EFV-containing regimen up to week 12 and then will be switched to TDF/FTC/RPV</description>
    <arm_group_label>Deferred Switch</arm_group_label>
    <other_name>Eviplera(r)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥18 years old and ability to sign informed consent

          -  Continuative treatment with EFV in combination with TDF/FTC or abacavir/lamivudine
             (ABC/3TC) for ≥180 days

          -  HIV-1 RNA viral load &lt; 50 copies/mL in two consecutive determinations (including
             screening)

          -  No history of treatment failure and/or evidence of any mutations associated with
             resistance to NRTI or NNRTI

          -  No contraindication to treatment with study drugs

          -  Any one of the following conditions:

             (i) Altered scores in depression, quality of sleep or anxiety tests (ii) Alteration in
             1 or more domains as assessed by neuropsychological assessment

        Exclusion Criteria:

          -  Ongoing treatment or predictable need of treatment with proton pump inhibitors

          -  New AIDS defining condition diagnosed within the 21 days prior to screening

          -  Previous diagnosis of AIDS dementia complex

          -  Current alcohol or substance dependence

          -  Major psychiatric disorders

          -  Decompensated cirrhosis

          -  Plasma creatinine &gt;1.2 mg/dl or estimated glomerular filtration rate &lt;60 ml/min (MDRD
             formula)

          -  AST, ALT or plasma bilirubin &gt;3 times upper limit of normal

          -  Any other clinical condition or prior therapy that would make the subject unsuitable
             for the study or unable to comply with the dosing/food requirements
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Giuseppe Lapadula, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>AO San Gerardo of Monza</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andrea Gori, MD</last_name>
    <role>Study Director</role>
    <affiliation>AO San Gerardo of Monza</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Giuseppe Lapadula, MD, PhD</last_name>
    <phone>+39 039 233 9320</phone>
    <email>g.lapadula@hsgerardo.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Andrea Gori, MD</last_name>
    <phone>+39 039 233 9313</phone>
    <email>andrea.gori@unimib.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Clinic of Infectious Diseases, AO San Gerardo</name>
      <address>
        <city>Monza</city>
        <state>MB</state>
        <zip>20900</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica di Malattie Infettive, Ospedale San Martino</name>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Antonio Di Biagio</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AO San Paolo - University of Milan</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Antonella d'Arminio Monforte, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale San Raffaele - Università Vita-Salute</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Antonella Castagna</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Adriano Lazzarin, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Policlinico Gemelli - Catholic University of Rome</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Simona Digiambenedetto, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Amedeo di Savoia - University of Turin</name>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Stefano Bonora, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 20, 2014</study_first_submitted>
  <study_first_submitted_qc>January 20, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 22, 2014</study_first_posted>
  <last_update_submitted>January 20, 2014</last_update_submitted>
  <last_update_submitted_qc>January 20, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 22, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Azienda Ospedaliera San Gerardo di Monza</investigator_affiliation>
    <investigator_full_name>Giuseppe Lapadula</investigator_full_name>
    <investigator_title>M.D. Ph.D</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Efavirenz</mesh_term>
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Rilpivirine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

